<DOC>
	<DOCNO>NCT00326157</DOCNO>
	<brief_summary>This pilot study design order evaluate safety efficacy AmBisome® load dose regimen , weekly administration schedule initial phase allogeneic stem-cell transplant case occurrence graft versus host disease ( GvHD ) , high risk period far severe fungal infection development concern .</brief_summary>
	<brief_title>PROPHESSOR : AmBisome Antifungal Primary Prophylaxis Treatment High Risk Patients Undergoing Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>This pilot study design order evaluate safety efficacy AmBisome® load dose regimen , weekly administration schedule initial phase allogeneic stem-cell transplant case occurrence GvHD , high risk period far severe fungal infection development concern .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>Male female patient age 18 year Patients hematological malignancy undergo allogeneic stem cell transplantation donor human leukocyte antigen ( HLA ) identical sibling ; source stem cell include either peripheral blood bone marrow No evidence fungal infection chest compute tomography ( CT ) scan sinus Xray baseline Patients sign symptom fungal infection previous proven probable invasive fungal infection ( IFI ) Females childbearing potential must surgically incapable pregnancy , practise method birth control , agree abstain heterosexual intercourse participate study , negative pregnancy test ( blood urine ) baseline An understanding study agreement patient give write informed consent Ability agreement comply study requirement Patient willing attend hospital appointment injection ( infusion perform hospital , strict medical supervision ) . All patient hospitalise prior , remain hospital least one day , first infusion . Known hypersensitivity amphotericin B , particular know history anaphylactic reaction amphotericin B Patients undergoing cord transplantation Creatinine &gt; 2.0 mg/dL Patient moderate severe liver disease define AST ALT &gt; 5 time upper limit normal ( ULN ) Patients unlikely survive 1 month Patients receive systemic antifungal therapy within 15 day prior inclusion Any severe cardiovascular disease ( arrhythmias , particular ) may constitute contraindication AmBisome® administration Any severe disease hematological disease describe second point inclusion criterion , investigator 's judgement may interfere study evaluation affect patient 's safety Pregnant nursing female Patients previously include study Patients take investigational drug last 30 day prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>antifungal primary prophylaxis treatment</keyword>
	<keyword>allogeneic stem-cell transplantation</keyword>
	<keyword>antifungal primary prophylaxis treatment high risk patient undergo allogeneic stem-cell transplantation</keyword>
</DOC>